当前位置：   首页 > 需求大厅

 >  特色服务 

 >  信息服务 

文献名称： 1.Clin Pharmacol Ther. 2017 Aug;102(2):238-245. doi: 10.1002/cpt.696. Epub 2017 May 26. Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now. Patrono C1, Baigent C2. 2、Pharmacoepidemiol Drug Saf. 2011 Dec;20(12):1225-36. doi: 10.1002s.2227. Epub 2011 Oct 3. Stroke risk and NSAIDs: a systematic review of observational studies. Varas-Lorenzo C1, Riera-Guardia N, Calingaert B, Castellsague J, Pariente A, Scotti L, Sturkenboom M, Perez-Gutthann S. 3.Int J Clin Pract Suppl. 2003 Apr;(135):43-9. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Henry D1, McGettigan P. 4.Int J Clin Pract Suppl. 2003 Apr;(135):32-7. Risk factors associated with the development of gastroduodenal ulcers due to the use ofNSAIDs. Wolfe MM1. 要求：将符合名称的文献上传PDF格式，先到先得   [更多]

1.盐酸可乐定缓释片   厂家：力品药业（厦门）股份有限公司  需要这个品种2022最新的药品说明书2.脂肪乳氨基酸（17）葡萄糖（19%）注射液    厂家：Fresenius Kabi AB  需要这个品种2022最新的药品说明书3.盐酸莫西沙星滴眼液   厂家：沈阳兴齐眼药股份有限公司 和 北京汇恩兰德制药有限公司  需要这个品种2022最新的药品说明书4.复方氨基酸注射液（20AA）   厂家：内蒙古白医制药股份有限公司    需要这个品种2022最新的药品说明书5.利丙双卡因乳膏，厂家：四川海思科制药有限公司，要一致性过评的说明书（有一致性评价标志）6.利丙双卡因乳膏，厂家：珠海莱奇生物科技有限公司，要一致性过评的说明书（有一致性评价标志）7.小儿复方氨基酸注射液(18AA-Ⅱ)，需要这个品种2020最新的药品说明书备注：上述说明书书均需要清晰附件类型。   [更多]

1悬赏的药品注册信息为2013年1月1日之后不批准、退审的药品注册信息,以及补充药品注册信息 2必须提供完整注册信息,以附件形式提交 3核实后如果正确,每个药品注册信息奖励100元 4投稿时请隐藏提交 5请勿在百度上直接搜索 6需是未收集的数据   [更多]

标题信息: 1、 Jian YIN, Xiao Bo YANG, Zai Xin CHEN, Yi Huan ZHANG.Total Synthesis of (-)-Tetrahydrolipstatin by the Tandem Mukaiyama-aldol Lactonization Chinese Chemical Letters Vol.16, No.11, pp 1448-1450, 2005 2.、Bidard, F. C. & Pierga, J. Y. Clinical utility of circulating tumor cells in metastatic breast cancer. J. Clin. Oncol. 33, 1622 (2015). 3、Schramm, A. et al. The DETECT Study Program: personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs). ASCO Meet. Abstr. 33, TPS11109 (2015). 4、.Ignatiadis, M. et al. Abstract OT1-2-02: trastuzumab in HER2-negative early breast cancer as adjuvant treatment for circulating tumor cells (CTCs) (Treat CTC). Cancer Res. 75, OT1-2–02 (2015). 5、Pharmacokinetics, safety, and tolerability of a rapid infusion of i.v. ibuprofen in healthy adults. 备注：将符合标题的PDF上传，先到先得   [更多]

搜集2020.10-2020.12药监局等机构官方公布的法规文件。 具体要求可私聊。   [更多]

1、PDF文件，要求：无水印，完整，清晰，来源可靠（非讨论稿等），非网上百度所得，尽量为最新版的炮制规范。 2、45元一个省份的中药饮片炮制规范，目前总共需要10个省份的资料。 3、需要炮制规范的省份目录：山西省、湖北省、湖南省、海南省、陕西省、青海省、内蒙古自治区、西藏自治区、宁夏回族自治区、新疆维吾尔自治区   [更多]

《湖南省中药饮片炮制规范》（2021年版）电子版全件一份   [更多]

1. （7）G G, Shapiro ，Effects of albuterol and procaterol on exercise-induced asthma，Annals of allergy 65(4):273-6 . November 1990. 2. G G, Shapiro ，Effects of albuterol and procaterol on exercise-induced asthma，Annals of allergy 65(4):273-6 . November 1990. 3. 1.NAFLD in Asia—as common and important as in the West 4. Fundamentals of the chemotherapy of trichomoniasis and amebiasis with ornidazole 5. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism 6. [1] Cheesman EH, Blanchette MA, Ganey MV, Maheu LI, Miller SJ, Watson AD. Technetium-99m ECD: ester-derivatizeddiamine-dithiolTc complexesforimaging brain perfusion [Abstract].J Nucl Med, 1988, 29:788. 7. [2] Demonceau G, Leveille J, De Roo M et al. Comparison of Tc-99m-ECD and Tc-99m-HMPAO: First human resulte[Abstract]. J Nucl Med, 1988, 29(5): 747. 8. standards of medical care in diabetic peripheral neuropathy 9. 2017年中药饮片行业发展蓝皮书   [更多]

文献标题及相关内容 1、Temperature-sensitive liposomes for codelivery of tamoxifen and imatinib for synergistic breast cancer treatment（doi: 10.1080/08982104.2018.1502315） 2、 Hyaluronated Imatinib Liposomes with Hybrid approach to Target CD44 and P-gp Overexpressing MDR Cancer: An In-vitro, In-vivo and Mechanistic Investigation（doi: 10.1080/1061186X.2018.1497039） 3、Novel imatinib-loaded silver nanoparticles for enhanced apoptosis of human breast cancer MCF-7 cells. Artif Cells Nanomed Biotechnol（doi: 10.1080/21691401.2016.1202257） 4、Man-Fung Yuen, MD, PhD.Hepatocellular Carcinoma: A Global Perspective.2018 ASCO 5、CS-386の安全性試験実験動物に対する急性,亜急性ならびに慢性毒性試験(原著論文) 増田裕 (三共), 木村邦男 , 山下和男 , 金丸三記雄 , 松沼尚央 三共研究所年報 (1341-741X)30巻 Page175-192(1978.12） 6、吉田 勇 ほか Jpn J Antibiot, 63(6),457-479,2010 备注：提供PDF原件电子档，先到先得   [更多]

1、American Conference of Governmental Industrial Hygienists TLVs and BEIs. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH, 2008, 2、内容：Totsuka K，Furukawa M，Furuya N，et al. PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial （3）.45th Intersci Conf Antimicrob Agents Chemother（ICAAC）（Dec 16-19. Washington，D.C.），2005，Abst L-579标题 PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial； 3、PK–PD analysis of tebipenem pivoxil in clinical trials for pediatric patients. Jpn J Chemother. 2009;57(S-1):186–91. 4、Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. González MA1, Straughan AB. 5、Single dose study of the bioequivalence of two sustained-release theophylline formulations. Contreras J, Pérez N, González R, Ontivero E, López M. Arzneimittelforschung. 1998 Mar;48(3):259-62. 6、National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information., AD277-689 7、Graul, A.; Castaner, J.; Atorvastatin Calcium. Drugs Fut 1997, 22, 9, 956. 8、Formulation And Evaluation of Topical Aceclofenac Gel Using Different Gelling Agent（JAPAN PATEL1*, BRIJESH PATEL1, HARDEEPSINGH BANWAIT1, KAUSHAL PARMAR1,MANISH PATEL2 Department of Pharmaceutics, Sat Kaival College of Pharmacy, Sarsa, Anand, Gujarat, India Nootan Pharmacy College, Visnagar, Gujarat, India） 9、NCCN pediatric neuroblastoma practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Dec;10(12):1813-22 10、Preliminary studies on toxic effects of some vulcanizing accelerators 11、Dose Dumping Dose dumping is an increased concern with drugs manufactured as modified-release (MR) formulations, that is, where drug   [更多]